EUVIMEDEUVIMED entdecken
Open Access

Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level

Nicholas A Turner iD, Jay Krishnan, Alicia Nelson, Christopher R Polage, Ronda L Cochran, Lucy Fike, David T Kuhar, Preeta K Kutty, Rachel L Snyder, Deverick J Anderson

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Nicholas A Turner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Two-step testing for Clostridioides difficile infection (CDI) aims to improve diagnostic specificity but may also influence reported epidemiology and patterns of treatment. Some providers fear that 2-step testing may result in adverse outcomes if C. difficile is underdiagnosed.

Methods

Our primary objective was to assess the impact of 2-step testing on reported incidence of hospital-onset CDI (HO-CDI). As secondary objectives, we assessed the impact of 2-step testing on C. difficile–specific antibiotic use and colectomy rates as proxies for harm from underdiagnosis or delayed treatment. This longitudinal cohort study included 2 657 324 patient-days across 8 regional hospitals from July 2017 through March 2022. Impact of 2-step testing was assessed by time series analysis with generalized estimating equation regression models.

Results

Two-step testing was associated with a level decrease in HO-CDI incidence (incidence rate ratio, 0.53 [95% confidence interval {CI}, .48–.60]; P < .001), a similar level decrease in utilization rates for oral vancomycin and fidaxomicin (utilization rate ratio, 0.63 [95% CI, .58–.70]; P < .001), and no significant level (rate ratio, 1.16 [95% CI, .93–1.43]; P = .18) or trend (rate ratio, 0.85 [95% CI, .52–1.39]; P = .51) change in emergent colectomy rates.

Conclusions

Two-step testing is associated with decreased reported incidence of HO-CDI, likely by improving diagnostic specificity. The parallel decrease in C. difficile–specific antibiotic use offers indirect reassurance against underdiagnosis of C. difficile infections still requiring treatment by clinician assessment. Similarly, the absence of any significant change in colectomy rates offers indirect reassurance against any rise in fulminant C. difficile requiring surgical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridioides difficileClostridium InfectionsHumansClostridioidesLongitudinal StudiesAnti-Bacterial AgentsDelivery of Health Care

Stichwörter der Autor:innen

Clostridioides difficile2-step testinginterrupted time series analysis

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.
  • Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University Medical Center, Durham, North Carolina.
  • Duke Clinical Microbiology Laboratory, Duke University Health System, Durham, North Carolina.
  • Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.

ORCID-Profile: Nicholas A Turner

Förderung

  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Turner, N. A., Krishnan, J., Nelson, A., Polage, C. R., Cochran, R. L., Fike, L., Kuhar, D. T., Kutty, P. K., Snyder, R. L., & Anderson, D. J. (2023). Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad334

Vancouver

Turner NA, Krishnan J, Nelson A, Polage CR, Cochran RL, Fike L, et al. Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad334

BibTeX
@article{Turner2023,
  author = {Turner, Nicholas A and Krishnan, Jay and Nelson, Alicia and Polage, Christopher R and Cochran, Ronda L and Fike, Lucy and Kuhar, David T and Kutty, Preeta K and Snyder, Rachel L and Anderson, Deverick J},
  title = {Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad334}
}
Kostenlos starten →